LATS2 and neoplasm: LncRNA sSNHG17 knockdown or gefitinib treatment caused a remarkable upregulation of LATS2 in xenograft tumours tissues, while this effect was further strengthened by SNHG17 silencing and gefitinib co-treatment (Fig. 8D).